Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Down 37.8% in March

Synaptogenix, Inc. (NASDAQ:SNPX) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 12,000 shares, a drop of 37.8% from the March 15th total of 19,300 shares. Currently, 0.9% of the company’s shares are sold short. Based on an average daily volume of 12,200 shares, the short-interest ratio is presently 1.0 days.

Synaptogenix Price Performance

Shares of NASDAQ SNPX opened at $2.24 on Thursday. Synaptogenix has a 12 month low of $1.84 and a 12 month high of $5.38. The company has a 50-day simple moving average of $2.62 and a 200-day simple moving average of $2.92. The company has a market cap of $3.11 million, a PE ratio of -0.21 and a beta of 1.07.

Synaptogenix (NASDAQ:SNPX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($4.36) earnings per share for the quarter, missing the consensus estimate of ($2.06) by ($2.30).

Hedge Funds Weigh In On Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC purchased a new stake in Synaptogenix, Inc. (NASDAQ:SNPX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.80% of Synaptogenix at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.34% of the company’s stock.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.